医药电商第一股药易购陷困局：B2B萎缩、C端难撑、研发收缩，半年报由盈转亏

新浪证券09-12

顶着“医药电商第一股”光环的药易购，正在经历上市以来最严峻的挑战。　　2025年上半年，药易购营收同比下滑3.06%，归母净利润亏损761.44万元，同比暴跌162.95%；扣非净利润更是骤降198.14%。尤其引人关注的是，其第一季度尚盈利418万元，第二季度却突然亏损超1179万元，业绩“变脸”之快，折射出背后经营压力的急剧上升。　　政策与市场的双重挤压　　“七统一”政策中“统一采购配送...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2566192561?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-12 14:50","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2566192561","market":"fut","top_or_hot":-1,"title":"医药电商第一股药易购陷困局：B2B萎缩、C端难撑、研发收缩，半年报由盈转亏","media":"新浪证券","content":"<div>\n<p>顶着“医药电商第一股”光环的药易购，正在经历上市以来最严峻的挑战。\n　　2025年上半年，药易购营收同比下滑3.06%，归母净利润亏损761.44万元，同比暴跌162.95%；扣非净利润更是骤降198.14%。尤其引人关注的是，其第一季度尚盈利418万元，第二季度却突然亏损超1179万元，业绩“变脸”之快，折射出背后经营压力的急剧上升。\n　　政策与市场的双重挤压\n　　“七统一”政策中“统一采购配送...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/aigcy/2025-09-12/doc-infqfnme2277846.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医药电商第一股药易购陷困局：B2B萎缩、C端难撑、研发收缩，半年报由盈转亏</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医药电商第一股药易购陷困局：B2B萎缩、C端难撑、研发收缩，半年报由盈转亏\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-12 14:50 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/aigcy/2025-09-12/doc-infqfnme2277846.shtml><strong>新浪证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>顶着“医药电商第一股”光环的药易购，正在经历上市以来最严峻的挑战。\n　　2025年上半年，药易购营收同比下滑3.06%，归母净利润亏损761.44万元，同比暴跌162.95%；扣非净利润更是骤降198.14%。尤其引人关注的是，其第一季度尚盈利418万元，第二季度却突然亏损超1179万元，业绩“变脸”之快，折射出背后经营压力的急剧上升。\n　　政策与市场的双重挤压\n　　“七统一”政策中“统一采购配送...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/aigcy/2025-09-12/doc-infqfnme2277846.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0250","symbol_name":"批发","start_time":0,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-09-12/doc-infqfnme2277846.shtml","article_id":"2566192561","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566192561","pubTimestamp":1757659800,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"顶着“医药电商第一股”光环的药易购，正在经历上市以来最严峻的挑战。　　2025年上半年，药易购营收同比下滑3.06%，归母净利润亏损761.44万元，同比暴跌162.95%；扣非净利润更是骤降198.14%。尤其引人关注的是，其第一季度尚盈利418万元，第二季度却突然亏损超1179万元，业绩“变脸”之快，折射出背后经营压力的急剧上升。　　从“医药电商第一股”到如今深陷“增收不增利”、B、C两端皆承压的困局，药易购正站在转型的关键十字路口。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300937":"药易购","BK0250":"批发"},"translate_title":"Yaoyigou, the first pharmaceutical e-commerce stock, is in trouble: B2B shrinking, C-end difficulty, R&D shrinking, and the semi-annual report turned from profit to loss","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300937":1},"content_text":"顶着“医药电商第一股”光环的药易购，正在经历上市以来最严峻的挑战。\n　　2025年上半年，药易购营收同比下滑3.06%，归母净利润亏损761.44万元，同比暴跌162.95%；扣非净利润更是骤降198.14%。尤其引人关注的是，其第一季度尚盈利418万元，第二季度却突然亏损超1179万元，业绩“变脸”之快，折射出背后经营压力的急剧上升。\n　　政策与市场的双重挤压\n　　“七统一”政策中“统一采购配送”的要求，直接冲击了药易购的核心B2B电商业务。与此同时，院外市场竞争日趋白热化——不仅传统流通企业如九州通、益丰药房持续施压，京东健康、阿里健康等互联网巨头也在加速分食市场。药易购的传统优势阵地正在被多方夹击。\n　　B2B业务持续收缩，C端尚未成气候\n　　尽管公司持续推进“B转C”战略转型，但2024年财报显示，其B端业务仍占总营收97%以上。2025年上半年，B2B电商收入同比下滑5.84%，数字化分销收入减少3.34%，显示主业增长动力不足。\n　　C端业务虽呈现爆发式增长——线上零售收入同比激增225%，但基数过低，营收占比仅1.3%，难以扛起大梁。更值得警惕的是线下门店的“增量不增收”困境：直营店在一年内新增425家，收入反而下滑10.71%，揭示出单店运营效率正在急剧恶化。\n　　关键指标现“背离”，电商收入反降\n　　一个值得深究的现象是：2025年上半年，药易购电商业务的客户数、订单数、月活等多项指标均实现同比增长，但电商业务总收入却同比下降5.89%。这一“背离”暗示其流量转化效率和货币化能力正在减弱，平台竞争力面临考验。\n　　“三费”高企，研发投入反大幅收缩\n　　亏损背后，“三费”大幅上升成为业绩主要拖累。销售费用同比上涨46.25%，管理费用和财务费用也均有增长。而研发费用则同比骤降39.73%，研发费用率仅0.26%，与其一再强调的“科技驱动”战略明显不符。研发人员数量及薪酬总额也在下降，显示出公司对长期技术投入的力度正在减弱。\n　　总结\n　　从“医药电商第一股”到如今深陷“增收不增利”、B、C两端皆承压的困局，药易购正站在转型的关键十字路口。在政策收紧与市场竞争日趋残酷的背景下，能否找到新的增长引擎、有效控制成本、重回研发轨道，将决定其能否在行业洗牌中存活下来。\n　　本文结合AI工具生成\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：AI观察员","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566192561","isCrawlerRequest":true}